HCM
SNDX icon

Highbridge Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Highbridge Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-28,328
Closed -$248K – 1673
2017
Q4 		$248K Buy
+28,328
New +$280K ﹤0.01% 1360

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Highbridge Capital Management's SNDX Position: Q1 2018 in Review

Highbridge Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2018, closing a stake of 28,328 shares — an estimated $248K sold.

Highbridge Capital Management first reported a position in SNDX in Q4 2017 and held it in 1 quarter. The position peaked at $248K in Q4 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q1 2018.

  • Highbridge Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 28,328 Syndax Pharmaceuticals shares in Q1 2018, an estimated $248K.
  • Highbridge Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Highbridge Capital Management's Syndax Pharmaceuticals position peaked at $248K in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.